Should I buy Bionano Genomics stock in 2025?

What is Bionano Genomics?

How much is the Bionano Genomics stock?

The price of Bionano Genomics stock is slightly down this week. As of now, BNGO trades at $3.65, marking a 1.35% drop over the past 24 hours but showing an increase of 0.83% on the week.

Investors should note: Bionano Genomics is a highly volatile and speculative stock, making careful research essential before making investment decisions.

Our full analysis on the Bionano Genomics stock

After an exhaustive review of Bionano Genomics' most recent financial reporting, its stock performance trajectory over the past three years, and a systematic comparison of key industry benchmarks and competitors—leveraging our proprietary analytical frameworks—the current outlook for Bionano Genomics (NASDAQ: BNGO) merits close attention. By blending a rigorous assessment of financial indicators, technical trade signals, broader market developments, and strategic business execution, we aim to clarify the potential for this innovative genomics technology stock. So, why might Bionano Genomics once again emerge as a compelling entry point within the life sciences and biotechnology equipment sector in 2025?

Recent Performance and Market Context

Despite marked volatility, Bionano Genomics' price action in 2024–2025 appears to be forming a new base, potentially laying the groundwork for a future re-rating. As of 30 May 2025, BNGO trades at $3.65, registering an uptick of +0.83% over the past week, though the six-month and one-year returns remain under pressure at –76.60% and –93.79%, respectively. The 52-week price range demonstrates significant past volatility ($2.68–$60.60), reflecting cycles of exuberance and consolidation that are typical in high-growth, high-risk biotech names.

Recent months have seen critical strategic moves, including a successful 1-for-60 reverse stock split to secure ongoing NASDAQ listing and a timely $10 million capital raise. These ensure continued access to public markets and operational flexibility. On the product front, 2025 is witnessing the full-scale commercial rollout of Stratys™, Bionano’s next-generation high-throughput optical genome mapping (OGM) system, following the establishment of a crucial Category I CPT code for OGM procedures in the US—a key development in driving clinical adoption and reimbursement.

The sectoral backdrop is also turning increasingly favourable. Life sciences instrumentation is attracting renewed strategic investments globally, with the genomics space in particular projected to deliver a 24–27% compound annual growth rate to 2030. As health systems, research institutions, and precision medicine initiatives scale up demand for structural variant analysis, optical genome mapping is expected to take on a central role. Within this context, Bionano’s innovative technology pipeline is well placed to capitalise.

Technical Analysis

Technically, BNGO is exhibiting early signals of forming a potential bottom, having revisited and held multiple times the key support area of $3.61–$3.64. Short-term technical indicators, while not yet flashing buy signals, are showing improving risk/reward profiles:

• RSI (14d): 42.59 (nearing neutral from oversold), suggesting downside momentum is waning.
• MACD: –0.015 (bearish, but flattening), often preceding trend reversals when combined with other signals.
• Stochastics: 19.03, well within oversold territory, which historically has anticipated relief rallies.

Moving averages remain below trend (5d: $3.67, 20d: $3.74, 200d: $3.94), but the clustering of prices just above strong support indicates the possibility of a bullish structure forming. The primary near-term resistance bands are at $3.72–$3.81 and then $3.96–$3.97. A decisive move through these levels could trigger renewed momentum, underpinned by positive newsflow from product launches or commercial milestones.

In summary, short-term downside appears increasingly limited by robust technical support, and the setup may appeal to investors looking to gain exposure at a technical low with potential for significant upside should catalysts materialise.

Fundamental Analysis

From a fundamental perspective, Bionano Genomics displays several characteristics that underpin a positively-oriented long-term outlook:

• Revenue Trends: 2024 revenue of $30.8 million, down 15% year-on-year, was offset by a 1% rise in product revenues. Looking forward, management guides for 2025 revenue between $29–32 million, signalling stabilisation even as broader industry funding remains selective.
• Profitability Metrics: Despite reporting net losses (EPS TTM: –$53.53), Bionano materially improved its gross margin in Q4 2024 to 42% (versus 23% a year prior), and nearly halved its quarterly operating expenses ($15.4 million vs. $27.4 million YOY). These are clear indicators of sound cost discipline and strategic focus on scalable, high-margin growth.
• Valuation: The shares trade at highly depressed multiples (P/S: 0.22, P/B: 0.25), levels typically associated with distress but which can offer outsized re-rating potential if operational milestones are delivered. Notably, such valuation metrics are now considerably below sector norms.
• Competitive Strengths:
• Installed Base Growth: The OGM platform (Saphyr™ and Stratys™) installed base grew 14% to 371 systems in 2024.
• IP and Thought Leadership: With 336 OGM-related scientific publications (up 19% YOY) and clear leadership in optical mapping innovation, Bionano is setting the standard in its niche.

Combined, these metrics suggest that Bionano’s valuation is compelling for investors seeking asymmetric upside exposure to a disruptive genomics platform—particularly given the transition to a leaner, more operationally efficient organisation.

Volume and Liquidity

Bionano’s trading volume has averaged around 145,000 shares daily over the past three months, a figure that, while lower than peak years, affirms ongoing market attention. The low float (3.36 million shares) and compact market cap ($12.3 million) create an environment where positive news or strong buying interest can prompt rapid and outsized price movements. For traders and patient investors alike, this dynamic introduces the prospect of dynamic revaluation phases, especially around key data releases or product news. This liquidity structure means that smaller capital flows can drive significant price changes—an attractive feature when entering near technical lows.

Catalysts and Positive Outlook

Several near-term and structural catalysts underpin Bionano’s bullish thesis:

• Commercial Roll-out of Stratys™: The new system greatly enhances throughput and scalability, accelerating clinical and research adoption.
• Reimbursement Milestone: Introduction of a Category I CPT code for OGM is transformative for market access in the US, unlocking the potential for mainstream clinical utilisation and payer engagement.
• Cost Optimisation: Thanks to a strategic focus on key markets and recurring clients, Bionano achieved ~$100 million in annualised cost reductions since mid-2023, positioning it for increased operating leverage as revenues recover.
• High-growth Market: The OGM space is forecast to expand to between $0.5–1.8 billion by 2030, with Bionano holding a clear first-mover advantage as both incumbent and pioneer.
• Analyst Upgrades: Major brokers, including Maxim Group ($8 target, 20 May 2025) and HC Wainwright ($10 target, 9 April 2025), have issued constructive upgrades, with the analyst consensus pegging average upside potential of +98.6% from current levels.

Alongside these, a sustained upturn in the global genomics and life sciences investment cycle, plus regulatory tailwinds and heightened interest in precision medicine, provide robust macro support.

Investment Strategies

For active investors evaluating Bionano Genomics, several timeframes and tactical approaches are particularly worth noting:

• Short-term (Weeks to Months):
• Positioning close to the $3.61–$3.64 support, where the stock appears to be bottoming.
• Seeking a near-term trading bounce as oversold technicals resolve and positive company newsflow emerges.
• Medium-term (6–12 Months):
• Capitalising on the impact of commercial Stratys™ uptake, particularly as reimbursement pathways coalesce.
• Anticipating cyclical sector flows back to genomics as valuation gaps attract strategic and institutional interest.
• Long-term (12 Months+):
• Gaining exposure to a disruptive genomic platform as the OGM market scales, with Bionano’s technology potentially becoming standard of care in clinical cytogenetics and research.
• Potential strategic value as a takeover or partnership candidate, should the market accelerate or competitive interest intensify.

For each timeframe, the current share price represents an attractive base, especially for those anticipating meaningful catalysts before Q1 2026 (when cash runway is expected through).

Is it the Right Time to Buy Bionano Genomics?

Synthesising technical, fundamental, and strategic perspectives, Bionano Genomics seems to represent an excellent opportunity for investors seeking high-impact exposure to the rapidly evolving life sciences technology sector. Key strengths include:

• A sector-leading innovation pipeline and expanding installed base, validating commercial impact.
• Sharp improvements in cost discipline and operational focus, providing a launchpad for future profitability.
• Robust external validation and high analyst-conviction, pointing to potential share price upside well in excess of 90%.
• Macro and regulatory tailwinds supporting the adoption and reimbursement of OGM technologies.

Although the company’s journey has involved substantial volatility—characteristic of early-stage biotech—the current setup, valuation, and sector developments justify renewed interest. For patient, risk-tolerant investors seeking to capitalise on the next wave of genomics innovation, Bionano Genomics may be entering a new bullish phase—one where disciplined entry at current levels could yield disproportionate rewards as the story unfolds.

In an environment increasingly shaped by genomics-driven precision healthcare, Bionano Genomics stands out as a stock with both disruptive potential and multiple tailwinds accelerating its path to value realisation. For those looking ahead, this may well be one of the sector’s more compelling asymmetrical opportunities in 2025.

How to buy Bionano Genomics stock in Ireland?

Investing in Bionano Genomics (BNGO) shares from Ireland is straightforward and secure when you use a regulated online broker. You have two main options: cash (spot) buying, where you own the actual shares, or trading contracts for difference (CFDs), which allow you to speculate on price movements without holding the stock. Both methods can be accessed entirely online, with clear account funding and withdrawal processes. Whether you favour long-term investment or prefer short-term trading, regulated brokers offer tools to suit your goals. For those unsure which to choose, a broker comparison is available further down this page.

Cash buying

A cash purchase means you directly buy and own Bionano Genomics shares listed on the NASDAQ, with your holdings registered in your name or held on your behalf by the broker. Typically, Irish investors pay a fixed commission per order—usually around $5–$10 (or the equivalent in EUR, but for US stocks, charges are often in USD).

Example

Suppose the Bionano Genomics share price is $3.65 (current as of 30 May 2025). With a $1,000 investment, and assuming a brokerage commission of $5, you could buy around 273 shares ([$1,000 – $5] / $3.65 ≈ 273).
✔️ Gain scenario:
If the share price rises by 10%, your 273 shares will be worth approximately $1,100.
Result: You make a $100 gross gain, representing a +10% return on your original investment.

Trading via CFD

CFDs (Contracts for Difference) let you speculate on the price movements of Bionano Genomics without owning the actual shares. You open a position with your broker, and your profit or loss depends on the difference in price when you close the CFD. Instead of commissions, you typically pay a spread (the difference between buy and sell prices) and, if you hold your position overnight, a small daily financing fee.

Example

Let’s say you deposit $1,000 and use 5x leverage to open a CFD position on Bionano Genomics. This gives you exposure to $5,000 worth of shares.
✔️ Gain scenario:
If the stock rises by 8%, your position gains 8% × 5 = 40%.
Result: That’s a $400 gain on a $1,000 deposit (excluding spreads and overnight fees).

Final advice

Before you invest, it's important to compare brokers on costs, features, and conditions, as fees and terms can vary significantly. Whether you choose cash buying for direct ownership or CFDs for flexibility and leverage, the most suitable approach depends on your investment objectives and risk appetite. For a detailed comparison of regulated brokers suitable for investors in Ireland, check out our table further down this page. Happy investing!

Our 7 tips for buying Bionano Genomics stock

The latest news about Bionano Genomics

Bionano Genomics’ Q4 2024 results showed improved gross margin and reduced operating expenses despite falling revenue. The company reported Q4 revenue of $8.2 million, down 24% from the prior year, yet managed a notable gross margin increase to 42% (from 23% in Q4 2023), while cutting quarterly operating expenses nearly in half to $15.4 million. For the full year 2024, product revenue grew 1% year over year, indicating some stability in commercial product demand, and Bionano closed the year with $20.9 million in cash. These results confirm the company’s efforts to improve operational efficiency and maintain its financial runway, giving confidence to shareholders concerned about near-term liquidity.

Major US reimbursement progress was made, as a permanent AMA CPT code for optical genome mapping became effective January 2025. This milestone, based on the American Medical Association’s Category I code assignment, is a significant positive catalyst for Bionano’s OGM technology adoption in clinical practice in the US and potentially in Europe, including Ireland. The new code streamlines billing and supports broader acceptance of OGM-based diagnostics, a relevant development as Irish healthcare institutions often align with US reimbursement practices when evaluating novel genomic technologies for local use.

The launch of Stratys™, Bionano’s high-throughput system, represents a strong commercial step with direct market expansion potential. Having completed its full commercial rollout, Stratys™ targets large academic and hospital labs—segments well-represented across European medical research centers, including Ireland. This launch supports the expected installation of 15–20 new OGM systems in 2025, further growing Bionano’s installed base and ensuring recurring revenue from consumables and software, which are critical for establishing long-term relationships with European stakeholders.

Irish market participants benefit from a sharply improved analyst consensus, with recent upgrades and a price target nearly double current levels. Maxim Group raised its recommendation to “Buy” with an $8 target on 20 May 2025, and the average of seven covering analysts implies nearly 100% upside from current prices, with a consensus target of $7.33. This strong institutional endorsement, combined with the security’s unique position as a US-traded instrument eligible for inclusion in Irish and EU portfolios, makes Bionano Genomics an actionable candidate for Irish growth-oriented investors seeking US biotechnology exposure.

Bionano continues to strengthen its strategic positioning, highlighted by growth in installed OGM systems, high-impact publications, and deep cost reduction initiatives. At year-end 2024, the installed OGM base grew 14% y/y to 371 systems, and scientific output rose 19% with 336 publications. Bionano optimized its cost structure—achieving approximately $100 million in annualized savings since May 2023—while focusing on recurring, high-value customers. These moves solidify its technological leadership and lean operating profile, both key to securing additional traction and partnerships in markets with active genomics research ecosystems, such as Ireland.

FAQ

P. Laurore

Finance expert

Co-founder of HelloSafe and holder of a Master's degree in finance, Pauline has recognised expertise in personal finance, which she uses to help users better understand and optimise their financial choices. At HelloSafe, Pauline plays a key role in designing clear, educational content on savings, investments and personal finance. Passionate about financial education, Pauline strives, with every piece of content she oversees, to provide reliable, transparent and unbiased information for independent and informed financial management. To this end, she has tested over 100 trading platforms to help internet users make the right choices.